Newsroom | Novo Nordisk
Here journalists can access a concise and up-to-date overview of our company’s key facts, figures, and milestones.
www.novonordisk.comHere’s the latest on Novo Nordisk based on recent public reporting:
-
Novo Nordisk has been active in addressing access and pricing for Wegovy (semaglutide) amid broader market pressure. Reports note price adjustments and patient-access initiatives, including campaigns to promote authentic products and reduce counterfeit versions. These moves are part of ongoing efforts to balance patient access with pricing discipline.[1][3]
-
In late 2025, coverage and cost dynamics around Ozempic and Wegovy garnered attention, with outlets noting price changes for self-pay patients and retailer-specific pricing programs. The company also faced leadership churn headlines around CEO transitions and strategic reviews in some outlets.[2][3]
-
Independent coverage highlighted Novo Nordisk’s broader pipeline and diabetes/obesity portfolio, while also examining external pricing pressures and competitive dynamics, including signals from stock market commentary on trial results and revenue performance in recent quarters.[3]
-
Novo Nordisk’s official channels (Newsroom and U.S. media hub) provide the most authoritative updates on corporate announcements, product launches, and financial results. For the most precise and current statements, refer to their latest press releases and newsroom posts.[5][7][9]
If you’d like, I can pull the most recent press releases from Novo Nordisk’s site and summarize any key items (new approvals, clinical updates, or strategy shifts) with citations.